# Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

> **NCT00104091** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 56 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** TP-38

## Key facts

- **NCT ID:** NCT00104091
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-04
- **Final completion:** 2007-06
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2011-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104091, "Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00104091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*